Reported Saturday, UroGen Announced ATLAS Study Results At AUA 2024: UGN-102 Demonstrates Sustained Response In New And Recurrent Bladder Cancer Patients
Reported Saturday, UroGen Announced ATLAS Study Results At AUA 2024: UGN-102 Demonstrates Sustained Response In New And Recurrent Bladder Cancer Patients
- New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months
- 接受 UGN-102 治疗的新患者和复发患者在 12 个月时实现了相似的耐久性缓解率 (DOR)
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier methods the probabilities of remaining in complete response for both new and recurrent low-grade intermediate-risk non- muscle invasive bladder cancer (LG-IR-NMIBC) patients following treatment with investigational drug UGN-102 as primary therapy, with or without subsequent transurethral resection of the bladder tumor (TURBT) at 3 months.
致力于开发和商业化治疗尿路上皮癌和特种癌症的创新解决方案的生物技术公司UroGen Pharma Ltd.（纳斯达克股票代码：URGN）今天公布了对ATLAS试验的一项新分析结果，该研究使用卡普兰·迈尔方法估算了新发和复发的低度中等风险非肌肉浸润性膀胱癌（LG-IR-NMIBC）患者在接受研究药物 UGN-102 治疗后保持完全反应的可能性作为主要疗法，无论是否随后的经尿道切除术3 个月时出现膀胱肿瘤 (TURBT)。